Purpose. Medication errors reported to FDA as adverse events in which methotrexate was identified as a possible contributor were studied. Methods. All adverse-event reports submitted to FDA between November 1997 and December 2001 indicating potential medication errors involving methotrexate were analyzed to determine the indication for use, the type of error, and the point in the medication-use process where the error occurred. Results. A total of 106 cases of reported medication errors associated with methotrexate were identified, including errors resulting in 25 deaths (24%) and 48 other serious outcomes (45%). The most common types of errors involved confusion about the once-weekly dosage schedule (30%) and other dosage errors (22%). The most frequently involved indication for use was rheumatoid arthritis (42%). Of the errors, 39 (37%) were attributable to the prescriber, 21 (20%) to the patient, 20 (19%) to dispensing, and 18 (17%) to administration by a health care professional. Conclusion. A review of medication errors involving methotrexate revealed that errors occurred during all phases of use, often resulted from confusion about dosage, and often caused death or other serious adverse effects.
M ethotrexate is a folic acid antagonist used in the treatment of many medical conditions, including rheumatoid arthritis, 1 psoriasis, 2 and ectopic pregnancy. 3 It has also been proven effective against several forms of cancer, including acute lymphoblastic leukemia, 1 osteosarcoma, 4 and non-Hodgkin's lymphoma. 5 Doses of methotrexate (as the sodium salt) for rheumatoid arthritis can be as low as 2.5 mg, while 15 g/m 2 can be used (along with leucovorin rescue therapy) for osteosarcoma-a 10,000-fold difference. Scheduling of doses also varies widely, from cyclical protocols for cancer chemotherapy to weekly for rheumatoid arthritis and sarcoidosis. 6, 7 Adding to this complexity, methotrexate can be administered orally, intravenously, intramuscularly, or intrathecally.
Since folic acid plays a major role in cell division, its inhibition is associated with major toxicity to blood cells, the oral mucosa, hepatocytes, and lung and fetal tissue. Severe blood-cell toxicity is usually manifested as anemia, leucopenia, or thrombocytopenia and has been reported in up to 36% of lymphoma patients receiving methotrexate. 7 Oral ulceration, which can occur at the lower end of the methotrexate dosage spectrum, was seen in 11 of 29 patients treated for rheumatoid arthritis. 8 Methotrexate-related hepatotoxicity, which has occurred in 10% of sarcoidosis patients, 7 is not well correlated with liver-function test findings; biopsy is the only accurate method of assessing liver status. Pneumonitis, which is related to the cumulative dose, was reported in a literature review to occur in 5% of patients undergoing long-term therapy. 9 Methotrexate is such a potent teratogen that the manufacturer recommends that both male and female partners avoid exposure during pregnancy. 10 Frequent serious medication errors involving methotrexate have been reported, and some patients have died. [11] [12] [13] The errors have involved some aspect of the dosage regimen. Three recent fatal cases illustrate the hazards of failing to observe the weekly dosage schedule for rheumatoid arthritis. In one of these cases, a patient misunderstood the directions for use and took methotrexate 2.5 mg every 12 hours for six consecutive days instead of 2.5 mg every 12 hours for three doses each week. 14 In the second case, a patient misread the directions on a prescription bottle and took 10 mg every morning instead of every Monday. 14 In the third case, a physician prescribed methotrexate 15 mg daily instead of weekly, and the patient received nine doses. 15 Errors like these have been reported to organizations like the Institute for Safe Medication Practices (ISMP) and the United States Pharmacopeia, which in turn automatically notify FDA. 16 To evaluate the overall risk posed by methotrexate, errors need to be viewed in aggregate, along with their associated causes, to determine the most effective prevention strategies.
We studied medication errors reported to FDA as adverse events in which methotrexate was identified as a possible contributor.
Methods
The data for this study were extracted from the records of FDA's Adverse Event Reporting System (AERS). 17 AERS contains reports of medication errors and adverse events suspected to be associated with the administration of marketed prescription drugs and biological products (except vaccines). Reports to the system are spontaneous and voluntary, except that drug manufacturers are required to submit reports about those adverse events of which they become aware. 18 In 2001, FDA received 272,000 adverse-event reports. 19 FDA publishes quarterly data extracts of all reports received by AERS. 20 These extracts include information about patient demographics, the drug or drugs administered, the kinds of injuries or other adverse events that resulted, and the medical terms used to describe the reactions that occurred. However, the original report is withheld to prevent accidental release of personal infor-mation; in its place, FDA reviewers select terms from the Medical Dictionary for Regulatory Activities (MedDRA), an online source. 21, 22 From all reports entered into AERS from its inception in November 1997 through December 2001, we extracted every report naming methotrexate, a brand name for methotrexate, or a likely spelling variant. From the methotrexate reports, we selected reports in which methotrexate was listed as a suspect drug (rather than being listed as given concomitantly with other therapy) and that contained a MedDRA term suggesting a medication error may have taken place. The dictionary terms used to identify reports of a possible medication error were medication error, drug maladministration, drug interaction NOS (not otherwise stated), drug level NOS above therapeutic, accidental overdose, accidental exposure, and drug interaction potentiation.
Each report submitted to FDA permits the reporter to specify zero, one, or more of the following adverseevent outcomes: death, birth defect, disability, hospitalization, threat to the patient's life, intervention to prevent harm, and "other." Some reports do not indicate an outcome. We put each report into one of four mutually exclusive categories: (1) death, (2) disability or birth defect, (3) serious outcome (nonfatal), and (4) other or none stated. The category of serious outcome includes the FDA terms hospitalization (initial or prolonged), life-threatening, and required intervention to prevent harm. If an event could be put into more than one category, it was placed in the most significant one.
Because the database's abstracts do not contain enough detail for medication errors to be assessed, the full reports for possible cases of medication errors were requested from FDA under the Freedom of Information Act. These full reports formedafter FDA removed personal information-the basis of this study.
We defined a medication error as "any preventable event that may cause or lead to inappropriate medication use or patient harm." 23 After the elimination of duplicate reports (such as two manufacturers submitting published case reports about the same event), each case was reviewed to establish whether a medication error had occurred and was placed into one of four categories. "Definite" meant the case report contained an unambiguous direct statement by a reporting individual indicating that a medication error had occurred. "Probable" meant that unambiguous information indicated that a medication error had occurred (e.g., there was a statement that methotrexate for rheumatoid arthritis had been administered or taken daily instead of weekly, regardless of whether the reporter explicitly stated this was an error). "Possible" meant there was information indicating that a medication error may have occurred but that there could be other explanations as well. All other cases were classified as "unlikely," even if the patient suffered injuries that may have been related to administration of the drug, because information indicating an error was absent.
For each case we assessed the failure mode, or the point in the medication-use process where the error had occurred. The failure-mode categories were prescribing (including writing the order), dispensing, administering, and consuming and correspond to the major actors in the process: physician, pharmacist, nurse or caregiver, and patient. In addition, independent of the failure mode, we identified the type of error that had been made: confusion between daily and weekly administration, other dosage error, wrong drug, wrong route (e.g., intrathecal instead of intravenous), contraindication, labeled interaction, and other. If a report indicated that more than one type of error may have occurred, the most significant applicable error category was assigned. Drug interactions classified as possible medication errors were limited to those identified explicitly in the prescribing information. 6 Finally, we recorded the indication for which the drug was prescribed, either using the information in the "indication" block in the report or extracting it from the report narrative.
The data were analyzed with the SPlus 6.1 statistical package (Insightful Corp., Seattle, WA). The error reports were a population and do not have confidence intervals or standard errors.
Results
From 156 cases of adverse events identified in the AERS computer database, we classified 106 as medication errors ( Table 1 ). Cases that were eliminated included those involving duplicate copies of the same literature report submitted by different manufacturers, reports of possible new drug interactions about which no notice appeared in the product labeling, and adverse reactions that may have been related to the drug but for which no specific medication error was described or could be deduced. Patients for whom medication errors were reported had a mean age of 54 years, and 68% of them were women (Figure 1) .
The medication errors resulted in 25 deaths (24%). Outcomes classified as "other" included various skin abnormalities, depressed platelet counts, and slowed wound healing.
The most frequent indications for the drugs involved in errors were rheumatoid arthritis (44 cases [42%]), psoriasis (13 [12%]), and cancer (9 [9%] ). The many medical uses of methotrexate were also reflected in a wide spectrum of other indications for which at least one medication error was reported, including sarcoidosis, polyarthitis, ectopic pregnancy, and lupus erythematosus.
Overall, 52% of the reported errors involved some form of overdose, with the most common problem be-ing taking the drug daily instead of weekly (32 cases [30%]) ( Table 2 ). The potential for confusion in these error cases was increased by polypharmacy; 73% of the patients were taking 2 or more drugs (mean, 3.5 drugs).
A second type of error involved problems that may occur with any medication but produce serious adverse effects with methotrexate. These included instances of the wrong medication being given, fail-ing to note a contraindication, and using the wrong route of administration (giving methotrexate intrathecally when another route was intended).
The third major type of error involved drug interactions identified in the product labeling. The most common of the interactions that led to harm involved the coadministration of another drug with antifolate activity, especially trimethoprimsulfamethoxazole. The errors occurred in all four steps of the medication-use process: prescribing (39 cases [37%]), dispensing (20 [19%] ), administration (18 [17%]), and consuming (21 [20%] ). Errors in consuming evolved primarily out of patient confusion about the weekly dosage schedule (17 of 21 cases). The errors in prescribing were based on contraindications (6 of 39 cases), labeled interactions (18 of 39), dosage errors (6 of 39), and the wrong drug (2 of 39).
Discussion
Our study found that methotrexate is associated with significant preventable medication errors that warrant careful measures to improve patient safety. While some of the errors (those involving a contraindication, dispensing of the wrong drug, or use of the wrong route of administration) could happen for any drug and be hazardous, the distinctive weekly or cyclical dosage scheme and low therapeutic index constitute the most clearly identifiable risks of methotrexate and accounted for the largest number of preventable serious injuries and deaths.
The methotrexate error data have several limitations that should be considered in interpreting the study results. Because the error reports were voluntary and spontaneous, they provided little or no indication of the true number of errors that might be occurring annually in the United States or worldwide. We know of no studies that would provide a basis for estimating a reporting rate for medication errors. Studies of all types of adverse events suggest that there is 1 report for every 10 to 20,000 occurrences. 24, 25 Therefore, we suspect that errors were underreported in our study by some unknown amount.
The existence of an adverse-event report does not establish that the suspected drug caused the event; it only raises the possibility of an association. In the methotrexate error reports, the causal link was reasonable but still not certain. The reports contained either an explicit statement that an error had occurred or specific factual information indicating an error as defined by the study criteria. However, the reports were voluntary and varied widely in the amount of detail and length of follow-up.
An in-depth investigation involving medical records and interviews with participants might conclude that some cases classified as medication errors (especially among the 19 cases classified as possible) might not have constituted preventable errors. However, additional error cases not counted in this study might be identified in a more detailed study of the cases that were eliminated as being unlikely or among the thousands of adverse-event cases without a specific term suggesting a possible error.
These findings underscore ISMP's safe practice recommendations for methotrexate, 14 notably the need to talk to patients about the drug and make sure they have written information that explains the dosage schedule and the potential health consequences of a dosage error. In addition, ISMP recommends dispensing, when appropriate, the weekly dosage pack (Wyeth's Rheumatrix Dose Pack); it provides an additional tool for avoiding confusion over the dosage schedule.
Electronic alerts in prescriberorder-entry systems and pharmacy computer systems can signal clinicians to check for potential errors whenever oral methotrexate is ordered to be given more than once weekly. Serious drug interactions can be detected in the same manner. Dispensing methotrexate in the weekly dosage pack and communicating effectively with patients about unusual dosage regimens can reduce injuries. Clinicians should encourage feedback to ensure that the patient understands the weekly dosage schedule and that the medication should not be used "as needed" for symptom control. Patients should be given clear written instructions that name a specific day of the week for taking the drug, that emphasize the weeklynot daily-dosage schedule, and that explain the possible outcomes of a dosage error.
Conclusion
A review of medication errors involving methotrexate revealed that errors occurred during all phases of use, often resulted from confusion about dosage, and often caused death or other serious adverse effects. 
